Athena Cristina Ribigan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Athena Cristina Ribigan has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Florina Antochi
Neurology Department, University Emergency Hospital Bucharest, Splaiul Independentei, number 169, district 5, Bucharest ZIP code: 050098, Romania
4 shared publicationsRaluca Stefania Badea
Neurology Department, University Emergency Hospital Bucharest, Splaiul Independentei, number 169, district 5, Bucharest ZIP code: 050098, Romania,; Department of Clinical Neurosciences, University of Medicine and Pharmacy Carol Davila Bucharest, Dionisie Lupu street, number 37, district 1, Bucharest ZIP code: 020021, Romania
4 shared publications- Adina Magda Florea
Faculty of Automatic Control and Computer Science, National University of Science and Technology Politehnica Bucharest, 060042 Bucharest, Romania
2 shared publications - Alexandru Sorici
National University of Science and Technology Politehnica Bucharest
2 shared publications Amalia Ene
Neurology Department, University Emergency Hospital of Bucharest, Bucharest, Romania
2 shared publicationsAndreea Dragusin
Neurology Department, University Emergency Hospital of Bucharest, Bucharest, Romania
2 shared publications
Latest Publications
- Open Access
Chasing the Wrong Door for 30 Years: Is Suzetrigine the Key to Selective Pain Relief?
For a long time, pain management has relied on relatively old opioids and broad-spectrum non-opioids, which display efficacy gaps and non-negligible safety risks. This review explores why voltage-gated sodium channels, particularly NaV1.7 and NaV1.8, emerged as prime targets for pain relief, and why early development efforts failed. NaV1.7 was initially considered a promising target due to its role in nociception and genetic evidence linking it to pain disorders. However, clinical trials of selective NaV1.7 inhibitors have repeatedly failed. We explore the reasons for these failures and discuss the clinical shortcomings of non-selective blockers and early NaV1.7 inhibitors. In contrast, NaV1.8 has emerged as a much stronger drug target, because it is mostly limited to peripheral nerves, directly drives continuous pain signaling, and shows less apparent functional redundancy in specific nociceptive axonal compartments. Nevertheless, compensatory mechanisms involving NaV1.7, NaV1.9, and other conductances remain context-, tissue-, and disease-dependent. Suzetrigine, a highly selective inhibitor of this channel, recently gained regulatory approval for acute pain, marking a major breakthrough in non-opioid options, even though its Phase 3 efficacy was comparable to hydrocodone/acetaminophen rather than superior to it. Its clinical success is built on high selectivity, excellent pharmacokinetics, and a smart trial design that focused specifically on standardized postoperative pain models. While suzetrigine shows that NaV1.8 can be successfully targeted, it represents a regulatory and mechanistic victory rather than a complete replacement for opioids in daily practice. Progress in this field will ultimately require precise targeting, better pharmacology, and trials that better match patient phenotypes.
Open AccessChasing the Wrong Door for 30 Years: Is Suzetrigine the Key to Selective Pain Relief?
For a long time, pain management has relied on relatively old opioids and broad-spectrum non-opioids, which display efficacy gaps and non-negligible safety risks. This review explores why voltage-gated sodium channels, particularly NaV1.7 and NaV1.8, emerged as prime targets for pain relief, and why early development efforts failed. NaV1.7 was initially considered a promising target due to its role in nociception and genetic evidence linking it to pain disorders. However, clinical trials of selective NaV1.7 inhibitors have repeatedly failed. We explore the reasons for these failures and discuss the clinical shortcomings of non-selective blockers and early NaV1.7 inhibitors. In contrast, NaV1.8 has emerged as a much stronger drug target, because it is mostly limited to peripheral nerves, directly drives continuous pain signaling, and shows less apparent functional redundancy in specific nociceptive axonal compartments. Nevertheless, compensatory mechanisms involving NaV1.7, NaV1.9, and other conductances remain context-, tissue-, and disease-dependent. Suzetrigine, a highly selective inhibitor of this channel, recently gained regulatory approval for acute pain, marking a major breakthrough in non-opioid options, even though its Phase 3 efficacy was comparable to hydrocodone/acetaminophen rather than superior to it. Its clinical success is built on high selectivity, excellent pharmacokinetics, and a smart trial design that focused specifically on standardized postoperative pain models. While suzetrigine shows that NaV1.8 can be successfully targeted, it represents a regulatory and mechanistic victory rather than a complete replacement for opioids in daily practice. Progress in this field will ultimately require precise targeting, better pharmacology, and trials that better match patient phenotypes.
- Open Access
- 24 June 2026
- Published by AMALTEA Medical Publishing House in Romanian Journal of Neurology
- Vol. 25 (2) , 191
Thyrotoxic hypokalemic periodic paralysis as the first manifestation of occult thyrotoxicosis: a case report
Background. Thyrotoxic hypokalemic periodic paralysis (THPP) is a rare, potentially life-threatening cause of sudden, generalized muscle weakness, precipitated by hypokalemia in the context of severe thyrotoxicosis. Case report. We report the clinical case of a young patient with abrupt-onset quadriplegia. Neurological examination revealed flaccid quadriplegia with preserved deep tendon reflexes. The patient reported a transient similar episode approximately 2 months earlier. He denied recent infections, trauma, or medication use. Brain and cervical spine CT were unremarkable. ECG detected sinus tachycardia with diffuse ST-segment depression. Laboratory evaluation revealed marked hypokalemia (K+ = 1.92 mmol/L) and severe hyperthyroidism (TSH = 0.000 µIU/mL, free T3 = 11.69 pg/mL). Prompt supplementation with potassium, antithyroid medication, and a beta-adrenergic blocker led to complete resolution of motor deficits, correction of electrolyte imbalance, and reversal of ECG abnormalities. Conclusions. Our case demonstrates THPP as a presenting manifestation of occult thyrotoxicosis and highlights the need to consider it in the differential diagnosis of sudden-onset muscle weakness.
- 24 June 2026
- Published by AMALTEA Medical Publishing House in Romanian Journal of Neurology
- Vol. 25 (2) , 191
Open AccessThyrotoxic hypokalemic periodic paralysis as the first manifestation of occult thyrotoxicosis: a case report
Background. Thyrotoxic hypokalemic periodic paralysis (THPP) is a rare, potentially life-threatening cause of sudden, generalized muscle weakness, precipitated by hypokalemia in the context of severe thyrotoxicosis. Case report. We report the clinical case of a young patient with abrupt-onset quadriplegia. Neurological examination revealed flaccid quadriplegia with preserved deep tendon reflexes. The patient reported a transient similar episode approximately 2 months earlier. He denied recent infections, trauma, or medication use. Brain and cervical spine CT were unremarkable. ECG detected sinus tachycardia with diffuse ST-segment depression. Laboratory evaluation revealed marked hypokalemia (K+ = 1.92 mmol/L) and severe hyperthyroidism (TSH = 0.000 µIU/mL, free T3 = 11.69 pg/mL). Prompt supplementation with potassium, antithyroid medication, and a beta-adrenergic blocker led to complete resolution of motor deficits, correction of electrolyte imbalance, and reversal of ECG abnormalities. Conclusions. Our case demonstrates THPP as a presenting manifestation of occult thyrotoxicosis and highlights the need to consider it in the differential diagnosis of sudden-onset muscle weakness.
- 21 March 2025
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Internet of Things Journal
- Vol. 12 (22) , 45995-46002
IoT-Driven Facial Expression Recognition for Personalized Healthcare in Industry 5.0
Facial emotion recognition (FER) plays a critical role in understanding human behavior, especially for individuals suffering from neurological disorders (NDs) like Parkinson’s disease (PD), Multiple Sclerosis (MS), and Stroke. Early and accurate detection of emotions is crucial for both the diagnosis of associated mood disorders and continuous monitoring. However, traditional methods often fall short in providing noninvasive, real-time solutions and lack the clinical expertise necessary to identify the specific emotion types associated with each ND category. In response, this research conducted under the ALAMEDA consortium presents an Internet of Things-based FER AI Toolkit designed to enhance early diagnosis and treatment for brain diseases. The toolkit is in line with the consortium’s clinical guidelines and provides a personalized, patient-focused solution that supports the goals of Industry 5.0 in healthcare. In line with Industry 5.0 principles, the FER AI Toolkit uses edge devices to collect real-time facial data while deep learning models running on cloud servers process this data. The recognized emotions are uploaded to the Semantic Knowledge Graph (SemKG) server. This allows healthcare professionals to make informed decisions based on real-time data. Additionally, the toolkit integrates seamlessly with key components of the ALAMEDA, including the Identity Authentication Manager (IAM) for secure access and the ALAMEDA Innovation Hub (AIH) for efficient resource management. By offering continuous and personalized healthcare insights, the FER AI Toolkit helps bridge the gap between diagnosis and patient well-being, ultimately advancing healthcare systems. Training materials and video demonstrations are available at https://drive.google.com/drive/folders/1-iUz7FE2IrKHt5nMl3oGjsrCtk7Ps2bM?usp=sharing for further learning.
- 21 March 2025
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Internet of Things Journal
- Vol. 12 (22) , 45995-46002
IoT-Driven Facial Expression Recognition for Personalized Healthcare in Industry 5.0
Facial emotion recognition (FER) plays a critical role in understanding human behavior, especially for individuals suffering from neurological disorders (NDs) like Parkinson’s disease (PD), Multiple Sclerosis (MS), and Stroke. Early and accurate detection of emotions is crucial for both the diagnosis of associated mood disorders and continuous monitoring. However, traditional methods often fall short in providing noninvasive, real-time solutions and lack the clinical expertise necessary to identify the specific emotion types associated with each ND category. In response, this research conducted under the ALAMEDA consortium presents an Internet of Things-based FER AI Toolkit designed to enhance early diagnosis and treatment for brain diseases. The toolkit is in line with the consortium’s clinical guidelines and provides a personalized, patient-focused solution that supports the goals of Industry 5.0 in healthcare. In line with Industry 5.0 principles, the FER AI Toolkit uses edge devices to collect real-time facial data while deep learning models running on cloud servers process this data. The recognized emotions are uploaded to the Semantic Knowledge Graph (SemKG) server. This allows healthcare professionals to make informed decisions based on real-time data. Additionally, the toolkit integrates seamlessly with key components of the ALAMEDA, including the Identity Authentication Manager (IAM) for secure access and the ALAMEDA Innovation Hub (AIH) for efficient resource management. By offering continuous and personalized healthcare insights, the FER AI Toolkit helps bridge the gap between diagnosis and patient well-being, ultimately advancing healthcare systems. Training materials and video demonstrations are available at https://drive.google.com/drive/folders/1-iUz7FE2IrKHt5nMl3oGjsrCtk7Ps2bM?usp=sharing for further learning.
- Open Access
- 29 September 2023
- Published by MDPI AG in Healthcare
- Vol. 11 (19) , 2656
Monitoring and Predicting Health Status in Neurological Patients: The ALAMEDA Data Collection Protocol
(1) Objective: We explore the predictive power of a novel stream of patient data, combining wearable devices and patient reported outcomes (PROs), using an AI-first approach to classify the health status of Parkinson’s disease (PD), multiple sclerosis (MS) and stroke patients (collectively named PMSS). (2) Background: Recent studies acknowledge the burden of neurological disorders on patients and on the healthcare systems managing them. To address this, effort is invested in the digital transformation of health provisioning for PMSS patients. (3) Methods: We introduce the data collection journey within the ALAMEDA project, which continuously collects PRO data for a year through mobile applications and supplements them with data from minimally intrusive wearable devices (accelerometer bracelet, IMU sensor belt, ground force measuring insoles, and sleep mattress) worn for 1–2 weeks at each milestone. We present the data collection schedule and its feasibility, the mapping of medical predictor variables to wearable device capabilities and mobile application functionality. (4) Results: A novel combination of wearable devices and smartphone applications required for the desired analysis of motor, sleep, emotional and quality-of-life outcomes is introduced. AI-first analysis methods are presented that aim to uncover the prediction capability of diverse longitudinal and cross-sectional setups (in terms of standard medical test targets). Mobile application development and usage schedule facilitates the retention of patient engagement and compliance with the study protocol.
- 29 September 2023
- Published by MDPI AG in Healthcare
- Vol. 11 (19) , 2656
Open AccessMonitoring and Predicting Health Status in Neurological Patients: The ALAMEDA Data Collection Protocol
(1) Objective: We explore the predictive power of a novel stream of patient data, combining wearable devices and patient reported outcomes (PROs), using an AI-first approach to classify the health status of Parkinson’s disease (PD), multiple sclerosis (MS) and stroke patients (collectively named PMSS). (2) Background: Recent studies acknowledge the burden of neurological disorders on patients and on the healthcare systems managing them. To address this, effort is invested in the digital transformation of health provisioning for PMSS patients. (3) Methods: We introduce the data collection journey within the ALAMEDA project, which continuously collects PRO data for a year through mobile applications and supplements them with data from minimally intrusive wearable devices (accelerometer bracelet, IMU sensor belt, ground force measuring insoles, and sleep mattress) worn for 1–2 weeks at each milestone. We present the data collection schedule and its feasibility, the mapping of medical predictor variables to wearable device capabilities and mobile application functionality. (4) Results: A novel combination of wearable devices and smartphone applications required for the desired analysis of motor, sleep, emotional and quality-of-life outcomes is introduced. AI-first analysis methods are presented that aim to uncover the prediction capability of diverse longitudinal and cross-sectional setups (in terms of standard medical test targets). Mobile application development and usage schedule facilitates the retention of patient engagement and compliance with the study protocol.
- Open Access
- 19 June 2023
- Published by MDPI AG in Healthcare
- Vol. 11 (12) , 1803
Shared Decision-Making to Improve Health-Related Outcomes for Adults with Stroke Disease
Stroke is one of the leading causes of disability and death worldwide, a severe medical condition for which new solutions for prevention, monitoring, and adequate treatment are needed. This paper proposes a SDM framework for the development of innovative and effective solutions based on artificial intelligence in the rehabilitation of stroke patients by empowering patients to make decisions about the use of devices and applications developed in the European project ALAMEDA. To develop a predictive tool for improving disability in stroke patients, key aspects of stroke patient data collection journeys, monitored health parameters, and specific variables covering motor, physical, emotional, cognitive, and sleep status are presented. The proposed SDM model involved the training and consultation of patients, medical staff, carers, and representatives under the name of the Local Community Group. Consultation with LCG members, consists of 11 representative people, physicians, nurses, patients and caregivers, which led to the definition of a methodological framework to investigate the key aspects of monitoring the patient data collection journey for the stroke pilot, and a specific questionnaire to collect stroke patient requirements and preferences. A set of general and specific guidelines specifying the principles by which patients decide to use wearable sensing devices and specific applications resulted from the analysis of the data collected using the questionnaire. The preferences and recommendations collected from LCG members have already been implemented in this stage of ALAMEDA system design and development.
- 19 June 2023
- Published by MDPI AG in Healthcare
- Vol. 11 (12) , 1803
Open AccessShared Decision-Making to Improve Health-Related Outcomes for Adults with Stroke Disease
Stroke is one of the leading causes of disability and death worldwide, a severe medical condition for which new solutions for prevention, monitoring, and adequate treatment are needed. This paper proposes a SDM framework for the development of innovative and effective solutions based on artificial intelligence in the rehabilitation of stroke patients by empowering patients to make decisions about the use of devices and applications developed in the European project ALAMEDA. To develop a predictive tool for improving disability in stroke patients, key aspects of stroke patient data collection journeys, monitored health parameters, and specific variables covering motor, physical, emotional, cognitive, and sleep status are presented. The proposed SDM model involved the training and consultation of patients, medical staff, carers, and representatives under the name of the Local Community Group. Consultation with LCG members, consists of 11 representative people, physicians, nurses, patients and caregivers, which led to the definition of a methodological framework to investigate the key aspects of monitoring the patient data collection journey for the stroke pilot, and a specific questionnaire to collect stroke patient requirements and preferences. A set of general and specific guidelines specifying the principles by which patients decide to use wearable sensing devices and specific applications resulted from the analysis of the data collected using the questionnaire. The preferences and recommendations collected from LCG members have already been implemented in this stage of ALAMEDA system design and development.
- Open Access
- 13 March 2022
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 56, 393.e5-393.e8
Posterior reversible encephalopathy syndrome – A pathology that should not be overlooked in the era of COVID-19
- 13 March 2022
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 56, 393.e5-393.e8
Open AccessPosterior reversible encephalopathy syndrome – A pathology that should not be overlooked in the era of COVID-19
- Open Access
- 23 January 2022
- Published by Springer Nature in Neurology and Therapy
- Vol. 11 (1) , 489
Correction to: Low Fluctuation of Symptoms May Delay Diagnosis of Myasthenia Gravis: A Case Series
- 23 January 2022
- Published by Springer Nature in Neurology and Therapy
- Vol. 11 (1) , 489
Open AccessCorrection to: Low Fluctuation of Symptoms May Delay Diagnosis of Myasthenia Gravis: A Case Series
- Open Access
- 23 December 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (51) , e28251
Febrile episode unmasking neuropsychiatric systemic lupus erythematosus with lytic lesions caused by secondary autoimmune myelofibrosis
Rationale: Systemic lupus erythematosus (SLE) is characterized by numerous immunological abnormalities that lead to multiorgan involvement. Central and peripheral nervous system manifestations are present in 8% to 92% of the cases of SLE. Furthermore, there have been reported cases of secondary autoimmune myelofibrosis associated with SLE. Patient concerns: We present the case of a 64-year-old female who was transferred from the Cardiology Department, where she was admitted for pericardial-pleural-peritoneal effusion after being discharged from another hospital following the resolution of a febrile episode. During hospitalization, she presented multiple oculomotor nerves palsies and weakness in the lower limbs. Serial cerebral magnetic resonance imaging (MRI) revealed extensive cerebral venous thrombosis. Nerve conduction studies showed sensory-motor axonal polyneuropathy. Thoracic MRI revealed a rare finding in patients with SLE – lytic lesions. Diagnoses: Extensive clinical, imaging, blood, and urine tests were performed. The patient exhibited pancytopenia, elevated inflammatory markers, hyperhomocysteinemia, mild hypoproteinemia, and severe proteinuria. The Hematology consultation ascertained that the peripheral blood smear and the bone marrow aspiration showed no alterations suggestive for a primary hematological disease and the thoracic vertebral-medullary MRI changes had a very low probability of representing osteolytic lesions in the context of plasma cells dyscrasia, but could not exclude their being result of a secondary autoimmune myelofibrosis. Immunology blood tests highlighted the presence of antinuclear antibodies and lupus anticoagulants. In this context, the Rheumatology consultation established the diagnosis of SLE with multiple complications. Interventions: The patient received treatment with cyclophosphamide. Outcomes: The ocular motricity problems and the paraparesis showed improvement. However, 1 week later, the patient developed weakness, dyspnea, and right lower quadrant abdominal pain. The abdominal-pelvic computed tomography scan indicated an acute right retroperitoneal hematoma with active bleeding for which she underwent arterial embolization of the spinal lumbar arteries with optimal result, but she died a few days later. Lessons: We chose to present this case in order to highlight the importance of interdisciplinarity in diagnosing and managing patients with SLE and multiorgan ailments, especially when faced with rare constellations of complications such as extensive cerebral venous thrombosis and osseous lytic lesions caused by secondary autoimmune myelofibrosis.
- 23 December 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (51) , e28251
Open AccessFebrile episode unmasking neuropsychiatric systemic lupus erythematosus with lytic lesions caused by secondary autoimmune myelofibrosis
Rationale: Systemic lupus erythematosus (SLE) is characterized by numerous immunological abnormalities that lead to multiorgan involvement. Central and peripheral nervous system manifestations are present in 8% to 92% of the cases of SLE. Furthermore, there have been reported cases of secondary autoimmune myelofibrosis associated with SLE. Patient concerns: We present the case of a 64-year-old female who was transferred from the Cardiology Department, where she was admitted for pericardial-pleural-peritoneal effusion after being discharged from another hospital following the resolution of a febrile episode. During hospitalization, she presented multiple oculomotor nerves palsies and weakness in the lower limbs. Serial cerebral magnetic resonance imaging (MRI) revealed extensive cerebral venous thrombosis. Nerve conduction studies showed sensory-motor axonal polyneuropathy. Thoracic MRI revealed a rare finding in patients with SLE – lytic lesions. Diagnoses: Extensive clinical, imaging, blood, and urine tests were performed. The patient exhibited pancytopenia, elevated inflammatory markers, hyperhomocysteinemia, mild hypoproteinemia, and severe proteinuria. The Hematology consultation ascertained that the peripheral blood smear and the bone marrow aspiration showed no alterations suggestive for a primary hematological disease and the thoracic vertebral-medullary MRI changes had a very low probability of representing osteolytic lesions in the context of plasma cells dyscrasia, but could not exclude their being result of a secondary autoimmune myelofibrosis. Immunology blood tests highlighted the presence of antinuclear antibodies and lupus anticoagulants. In this context, the Rheumatology consultation established the diagnosis of SLE with multiple complications. Interventions: The patient received treatment with cyclophosphamide. Outcomes: The ocular motricity problems and the paraparesis showed improvement. However, 1 week later, the patient developed weakness, dyspnea, and right lower quadrant abdominal pain. The abdominal-pelvic computed tomography scan indicated an acute right retroperitoneal hematoma with active bleeding for which she underwent arterial embolization of the spinal lumbar arteries with optimal result, but she died a few days later. Lessons: We chose to present this case in order to highlight the importance of interdisciplinarity in diagnosing and managing patients with SLE and multiorgan ailments, especially when faced with rare constellations of complications such as extensive cerebral venous thrombosis and osseous lytic lesions caused by secondary autoimmune myelofibrosis.
- Open Access
- 18 December 2021
- Published by Springer Nature in Neurology and Therapy
- Vol. 11 (1) , 481-487
Low Fluctuation of Symptoms May Delay Diagnosis of Myasthenia Gravis: A Case Series
Introduction Myasthenia gravis is an autoimmune disorder affecting neuromuscular transmission, and its hallmark is fluctuating muscular weakness affecting the ocular, bulbar, respiratory, or limb muscles. Our objective is to highlight the difficulties encountered in diagnosing this disorder in patients lacking this characteristic phenomenon. Methods Three cases of patients presenting with progressive weakness of bulbar and ocular muscles, in whom a lack of fluctuation delayed the diagnosis of myasthenia gravis, are described. Results Amyotrophic lateral sclerosis was considered in two of the patients, while cavernous sinus thrombosis was initially diagnosed in the third. Electrodiagnostic, pharmacologic, and serologic testing ultimately established the diagnosis of myasthenia gravis. Conclusion While the typical clinical pattern of myasthenia gravis is well known and easily recognizable, there are cases when the diagnosis, and thus the treatment, is delayed because of low or absent fluctuation of symptoms. The acknowledgment of this probably underestimated presentation is important for expeditious management.
- 18 December 2021
- Published by Springer Nature in Neurology and Therapy
- Vol. 11 (1) , 481-487
Open AccessLow Fluctuation of Symptoms May Delay Diagnosis of Myasthenia Gravis: A Case Series
Introduction Myasthenia gravis is an autoimmune disorder affecting neuromuscular transmission, and its hallmark is fluctuating muscular weakness affecting the ocular, bulbar, respiratory, or limb muscles. Our objective is to highlight the difficulties encountered in diagnosing this disorder in patients lacking this characteristic phenomenon. Methods Three cases of patients presenting with progressive weakness of bulbar and ocular muscles, in whom a lack of fluctuation delayed the diagnosis of myasthenia gravis, are described. Results Amyotrophic lateral sclerosis was considered in two of the patients, while cavernous sinus thrombosis was initially diagnosed in the third. Electrodiagnostic, pharmacologic, and serologic testing ultimately established the diagnosis of myasthenia gravis. Conclusion While the typical clinical pattern of myasthenia gravis is well known and easily recognizable, there are cases when the diagnosis, and thus the treatment, is delayed because of low or absent fluctuation of symptoms. The acknowledgment of this probably underestimated presentation is important for expeditious management.
- Open Access
- 8 December 2020
- Published by Wiley in Clinical Case Reports
- Vol. 9 (1) , 220-223
Anticoagulation‐refractory strokes and selective infarction pattern: What’s the link?
Stroke etiology in the form of a CAP should be actively explored, especially in the context of previous negative work‐up and anticoagulant‐refractory strokes. Dual antiplatelet therapy proved superior to anticoagulation for secondary prevention.
- 8 December 2020
- Published by Wiley in Clinical Case Reports
- Vol. 9 (1) , 220-223
Open AccessAnticoagulation‐refractory strokes and selective infarction pattern: What’s the link?
Stroke etiology in the form of a CAP should be actively explored, especially in the context of previous negative work‐up and anticoagulant‐refractory strokes. Dual antiplatelet therapy proved superior to anticoagulation for secondary prevention.